Eyenovia kicks off second Ph3 trial for pupil dilation tech

This article was originally published here

Eyenovia - updated logoEyenovia (NSDQ:EYEN) said this week that it finished patient enrollment in its Phase III Mist-1 trial and enrolled the first patient in its second Phase III trial for the company’s combination eye solution delivered as a micro-dose using its Optejet device.

The company is studying the therapy for pharmacologic mydriasis – pupil dilation for eye exams. The process is used in roughly 80 million office-based eye exams each year in the U.S., according to Eyenovia.

Get the full story at our sister site, Drug Delivery Business News.

The post Eyenovia kicks off second Ph3 trial for pupil dilation tech appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply